Search Results - "Aisner, D. L."

Evaluation of EGFR mutation status in cytology specimens: An institutional experience by Aisner, D. L., Deshpande, C., Baloch, Z., Watt, C. D., Litzky, L. A., Malhotra, B., Sepulveda, A. R., Langer, C., Evans, T., Van Deerlin, V. M.

“…Epidermal growth factor receptor (EGFR) mutation status has been shown to predict response to anti‐EGFR tyrosine kinase inhibitors in non‐small cell lung…”
Get full text

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC by Peters, T. L., Patil, T., Le, A. T., Davies, K. D., Brzeskiewicz, P. M., Nijmeh, H., Bao, L., Camidge, D. R., Aisner, D. L., Doebele, R. C.

“…EGFR mutant non-small cell lung cancer patients' disease demonstrates remarkable responses to EGFR-targeted therapy, but inevitably they succumb to acquired…”
Get full text

Functional requirement of p23 and Hsp90 in telomerase complexes by Holt, S E, Aisner, D L, Baur, J, Tesmer, V M, Dy, M, Ouellette, M, Trager, J B, Morin, G B, Toft, D O, Shay, J W, Wright, W E, White, M A

“…Most normal human diploid cells have no detectable telomerase; however, expression of the catalytic subunit of telomerase is sufficient to induce telomerase…”
Get full text

An Alternate Splicing Variant of the Human Telomerase Catalytic Subunit Inhibits Telomerase Activity by Yi, Xiaoming, White, Dennis M., Aisner, Dara L., Baur, Joseph A., Wright, Woodring E., Shay, Jerry W.

“…Telomerase, a cellular reverse transcriptase, adds telomeric repeats to chromosome ends. In normal human somatic cells, telomerase is repressed and telomeres…”
Get full text

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer by O'Neil, B H, Scott, A J, Ma, W W, Cohen, S J, Aisner, D L, Menter, A R, Tejani, M A, Cho, J K, Granfortuna, J, Coveler, L, Olowokure, O O, Baranda, J C, Cusnir, M, Phillip, P, Boles, J, Nazemzadeh, R, Rarick, M, Cohen, D J, Radford, J, Fehrenbacher, L, Bajaj, R, Bathini, V, Fanta, P, Berlin, J, McRee, A J, Maguire, R, Wilhelm, F, Maniar, M, Jimeno, A, Gomes, C L, Messersmith, W A

“…Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and…”
Get full text

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer by O'Neil, B.H., Scott, A.J., Ma, W.W., Cohen, S.J., Aisner, D.L., Menter, A.R., Tejani, M.A., Cho, J.K., Granfortuna, J., Coveler, A.L., Olowokure, O.O., Baranda, J.C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D.J., Radford, J., Fehrenbacher, L., Bajaj, R., Bathini, V., Fanta, P., Berlin, J., McRee, A.J., Maguire, R., Wilhelm, F., Maniar, M., Jimeno, A., Gomes, C.L., Messersmith, W.A.

Get full text

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer by O'Neil, B.H., Scott, A.J., Ma, W.W., Cohen, S.J., Leichman, L., Aisner, D.L., Menter, A.R., Tejani, M.A., Cho, J.K., Granfortuna, J., Coveler, L., Olowokure, O.O., Baranda, J.C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D.J., Radford, J., Fehrenbacher, L., Bajaj, R., Bathini, V., Fanta, P., Berlin, J., McRee, A.J., Maguire, R., Wilhelm, F., Maniar, M., Jimeno, A., Gomes, C.L., Messersmith, W.A.

Get full text

Telomerase regulation: not just flipping the switch by Aisner, Dara L, Wright, Woodring E, Shay, Jerry W

“…Significant research efforts have focused on the transcriptional regulation of the catalytic protein component of telomerase, hTERT (human telomerase reverse…”
Get full text

Lack of Cell Cycle Regulation of Telomerase Activity in Human Cells by Holt, Shawn E., Aisner, Dara L., Shay, Jerry W., Wright, Woodring E.

“…Conflicting reports have appeared concerning the cell cycle regulation of telomerase activity and its possible repression during quiescence and cell…”
Get full text

Two Inactive Fragments of the Integral RNA Cooperate To Assemble Active Telomerase with the Human Protein Catalytic Subunit (hTERT) In Vitro by Tesmer, Valerie M., Ford, Lance P., Holt, Shawn E., Frank, Bryan C., Yi, Xiaoming, Aisner, Dara L., Ouellette, Michel, Shay, Jerry W., Wright, Woodring E.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Telomerase Activity Does Not Always Imply Telomere Maintenance by Ouellette, Michel M., Aisner, Dara L., Savre-Train, Isabelle, Wright, Woodring E., Shay, Jerry W.

“…The forced expression of the catalytic subunit of human telomerase, hTERT, produces telomerase activity, allows telomere maintenance, and extends the cellular…”
Get full text

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer by Vaishnavi, Aria, Capelletti, Marzia, Le, Anh T, Kako, Severine, Butaney, Mohit, Ercan, Dalia, Mahale, Sakshi, Davies, Kurtis D, Aisner, Dara L, Pilling, Amanda B, Berge, Eamon M, Kim, Jhingook, Sasaki, Hidefumi, Park, Seung-il, Kryukov, Gregory, Garraway, Levi A, Hammerman, Peter S, Haas, Julia, Andrews, Steven W, Lipson, Doron, Stephens, Philip J, Miller, Vince A, Varella-Garcia, Marileila, Jänne, Pasi A, Doebele, Robert C

“…The authors employ targeted next-generation sequencing to identify driving oncogenic alterations in patients with lung cancer with no known oncogenes. They…”
Get full text

Loss of S100 antigenicity in metastatic melanoma by Aisner, Dara L., Maker, Ajay, Rosenberg, Steven A., Berman, David M.

“…Melanoma is a highly malignant disease that may initially present as a poorly differentiated metastatic tumor. Therefore, the S100 immunostain, immunoreactive…”
Get full text

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC by Patil, Tejas, Staley, Alyse, Nie, Yunan, Sakamoto, Mandy, Stalker, Margaret, Jurica, James M., Koehler, Kenna, Cass, Amanda, Kuykendall, Halle, Schmitt, Emily, Filar, Emma, Reventaite, Evelina, Davies, Kurt D., Nijmeh, Hala, Haag, Mary, Yoder, Benjamin A., Bunn, Paul A., Schenk, Erin L., Aisner, Dara L., Iams, Wade T., Marmarelis, Melina E., Camidge, D. Ross

“…Acquired MET gene amplification, MET exon 14 skip mutations, or MET fusions can emerge as resistance mechanisms to tyrosine kinase inhibitors (TKIs) in…”
Get full text

Telomere Dynamics in Cells with Introduced Telomerase: A Rapid Assay for Telomerase Activity on Telomeres by McChesney, Patricia A., Aisner, Dara L., Frank, Bryan C., Wright, Woodring E., Shay, Jerry W.

“…Most immortal cell lines derived from human cancers or transformed in vitro maintain telomeres by endogenous expression of telomerase. In the present work,…”
Get full text

Clinical Next-Generation Sequencing Assays for Solid Tumors by Hsiao, Susan J., MD, PhD, Aisner, Dara L., MD, PhD, Ewalt, Mark D., MD

Get full text

Molecular Pathology of Non–Small Cell Lung Cancer by Serracino, Hilary S., MD, Franklin, Wilbur A., MD, Aisner, Dara L., MD, PhD

“…Abstract This review offers an overview of the molecular pathology of lung cancer, with a focus on analyses that are most commonly part of the current clinical…”
Get full text